Medical technology company Pear Therapeutics Inc. has agreed to go public by merging with a blank-check company with ties to the Pritzker Vlock Family Office, betting on the growing role of prescription digital therapeutics. The proposed merger would give the combined company a pro forma equity value of about $1.6 billion. Pear Therapeutics is one of the leaders in prescription digital therapeutics, or PDTs. PDTs are designed and tested much like traditional prescription drugs but rely on software approved by health regulators to treat patients.
Read the full article: Pear Therapeutics to Go Public in Roughly $1.6B SPAC Deal //
Source: https://www.wsj.com/articles/pear-therapeutics-to-go-public-in-roughly-1-6-billion-spac-deal-11624359600